Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Moodys
Baxter

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Oxymetazoline hydrochloride; tetracaine hydrochloride - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for oxymetazoline hydrochloride; tetracaine hydrochloride and what is the scope of patent protection?

Oxymetazoline hydrochloride; tetracaine hydrochloride is the generic ingredient in one branded drug marketed by St Renatus and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oxymetazoline hydrochloride; tetracaine hydrochloride has twenty-three patent family members in thirteen countries.

There are three drug master file entries for oxymetazoline hydrochloride; tetracaine hydrochloride. One supplier is listed for this compound.

Summary for oxymetazoline hydrochloride; tetracaine hydrochloride
International Patents:23
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 3
Suppliers / Packagers: 1
Clinical Trials: 6
DailyMed Link:oxymetazoline hydrochloride; tetracaine hydrochloride at DailyMed
Recent Clinical Trials for oxymetazoline hydrochloride; tetracaine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPhase 4
Analytical Bio-Chemistry Laboratories, Inc.Phase 2
Triligent InternationalPhase 2

See all oxymetazoline hydrochloride; tetracaine hydrochloride clinical trials

Pharmacology for oxymetazoline hydrochloride; tetracaine hydrochloride

US Patents and Regulatory Information for oxymetazoline hydrochloride; tetracaine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
St Renatus KOVANAZE oxymetazoline hydrochloride; tetracaine hydrochloride SPRAY, METERED;NASAL 208032-001 Jun 29, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Mallinckrodt
Johnson and Johnson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.